Predictive Oncology (FRA:S1K) YoY EBITDA Growth : -22.24% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Predictive Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -22.24%.

Predictive Oncology's EBITDA per Share for the three months ended in Mar. 2024 was €-0.93.

Predictive Oncology YoY EBITDA Growth Historical Data

The historical data trend for Predictive Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology YoY EBITDA Growth Chart

Predictive Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

22.90

80.72

75.16

7.77

14.96

Predictive Oncology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															10.80	-6.78	29.01	25.39	-22.24

Predictive Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Predictive Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-3.069	-	-3.609)	/	\| -3.609 \|
=	14.96 %

Predictive Oncology's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.929	-	-0.76)	/	\| -0.76 \|
=	-22.24 %

Predictive Oncology YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology (FRA:S1K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

POAI:USA

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines